Optimi Health at H.C. Wainwright Conference
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The announcement has minimal direct market impact, as it is a routine investor-relations notice of conference participation rather than a disclosure of financial results, guidance, or clinical milestones. Any effect would be limited to incremental visibility for Optimi Health among institutional investors attending the H.C. Wainwright conference.
Optimi Health announced on September 8, 2026 that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, to be held September 14-16, 2026 at the Lotte New York Palace Hotel in New York City. The company stated that a presentation will be available on demand beginning Friday, September 11, 2026 at 7:00 a.m. ET, and that management will be available for one-on-one meetings throughout the conference. Investors interested in scheduling a meeting were directed to contact their H.C. Wainwright representative or register for the conference. Optimi Health is a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, producing GMP-grade MDMA and botanical psilocybin at Canada — Health Canada-licensed facilities in British Columbia, Canada. Its products are prescribed to patients in Australia under the Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program. The announcement is a routine investor-relations disclosure with no financial terms, guidance, or clinical data attached.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard